Sunday, 1 December 2024

Fasting & Cancer

 Does fasting help cancer? It depends.

Two forms of fasting- one, comprised of eschewing food but taking unrestricted water intake, and the other, called Fasting Mimicking Diet (FMD) have been shown to be useful.

How does it work?

Glucose, amino acids and certain hormones or hormone like substances are thought to encourage cancer growth, including insulin, IGF-1, and leptin. Think of these as anabolic pathways, which provide the nutrients and the drivers for cancer growth and survival. Turn them off, and the cancer cells are disdavantaged.

Note that I haven't mentioned fatty acids, non-intuitive though it may seem. Cancer cells are highly dependent on anaerobic metabolism, epitomised by the Warburg effect, which involves hijacking the glycolytic pathway (normally anaerobic) even in the presence of oxygen, and producing ATP therefrom. This is seen in fully 70-80% of cancer cells.

Conversely fatty acids are metabolised inside mitochondria by beta-oxidation and therefore is a highly aerobic process, not normally utilised by cancer cells.

The corollary is that cancer fighting diets must contain very little carb or protein and any calories, limited albeit in amount, must come from fat. This is exactly what happens with FMD, which consists of 300-1100 calories perday, derived from broths, soups, juices and nutty bars, with some herbal teas thrown in for taste.

It is thought that by abrogating the anabolic hormones mentioned above, you shut down two key canonical intracellular pathways- the PI3K-AKT-MTOR pathhway and the cAMP-Protein Kinase A pathway. Both are proliferatogenic and indispensable for cancer cells.

However, the claim that FMD alone will cure cancer is inaccurate. This diet works well in tandem with chemotherapy and radiotherapy, and must be administered during the peri-chemotherapy period, usually 48 hours before and 24 hours after. It stops the cancer cells from finding "escape" pathways to circumvent chemotherapeutic agents. But the piece-de-resistance of such diets is that it protects normal, healthy cells from being destroyed by chemo, while the cancer cells perish. 

That is to say, the normal cells display Differential Stress Resistance (DSR)  to cancer cells. At the onset of fasting, normal, non-cancerous cells go into a sort of hibernant, low metabolic state, which reduces their vulnerability to chemotherapeutic agents. As they are no longer actively taking up nutients, metabolising or dividing, they become relatively immune to chemo and radiotherapy.

You might well ask- does this work for all cancers? 

Unfortunately not. It's particularly effective for breast cancer, which is ER/PR positive, but not for ER/PR negative,  HER-2 positive cases. Thus, it potentiates the action of both Tamoxifen, without causing endomtrial hypertrophy, and Fulvestrant.

Similar benefits are seen for prostate and colon cancer.

If a relatively fat rich diet works, what about the ketogenic diet (4:1 fat:carb+protein in terms of weight)? After all, the blood ketone levels can rise by >0.5 mmol/L with FMDs.

Neurosurgeons here will know that ketogenic diets have considerable benefits for some intractable childhood epilepsies and has been advocated for certain gliomas/glioblastomas. However, in general, ketogenic diet does not work for cancers, and can worsen prognosis in melanomas. Hence, best avoided.

A few caveats. Most of the data for these findings were from animal, mainly murine studies and from yeasts. Human data is limited.

Secondly, some cancer patients are cachexic at treatment. They would be at risk from FMD like diets.

Thirdly, trying to achieve these metabolic benefits pharmacologically does not seem to work. The MTOR inhibitor Rapamycin (Sirolimus) is not generally useful for cancers.

Fourth, chronic calory restricted diets don't seem to work for cancer. FMD must coincide with the chemotherapy cycles. This is therefore intermittent fasting.


Saturday, 7 September 2024

2024 ACR/ACCP Guidelines on Treatment of SARD-ILDs

The ACR/ACCP committee looked at ILD associated with five common SARD categories:

1. Systemic Sclerosis (SSc)
2. RA
3. IIM (includes anti-synthetase syndromes and Immune mediated necrotising myositis).
4. Sjogren's
5. MCTD

Following is a summary of the recommendations:

For initiation of treatment:

1. MMF as first line choice to commence treatment in all categories. However, this may be tempered by extra-pulonary considerations, for example, rituximab may be preferred in RA with active joint disease.
2. Cyclophosphamide still among first line choices, but Rituximab preferred in all 5 categories due to equivalent results and lower incidence of side effects.
3. Steroids, either short term or long term, to be avoided in SSc.
4. Short term steroids acceptable in other categories, but not long term.
5. Tocilizumab, elevated to one of the first line choices in SSc and MCTD with SSc features.
6. In RA-ILD, Methotrexate, Leflunomide, anti-TNFs and Abatacept should not be used for treatment of ILD. There is discretion to use them for arthritis, but some panelists would withdraw them if incident ILD develops.
7. JAK inhibitors can be used as first line in IIM, and particularly useful in MDA-5 (JAKi include Tofacitinib, Baricitinib and Upadacitinib).
8. Similarly, calcineurin inhibitors, with tacrolimus preferred to ciclosporin, is amongst first line choices for IIM-ILD.
9. Nintedanib is now recommended as a first line choice in  SSc, but not others.
10. Azathioprine remains among first line choices for all categories, but is down in the pecking order for SSc, behind MMF, Rituximab and Tocilizumab.

For progression of ILD despite treatment:

1. If any of the first line Rx above has not been used, it may now be used, with the exception of Azathioprine.
2. Nintedanib can be used for all categories, on the grounds of PPF.
3. Tocilizumab may be used for progressive RA-ILD.
4. IVIG may be used for progressive IIM-ILD.
5. AHST may be considered at this point for SSc-ILD.
6. Pirfenidone may be considered, but only for progressive RA-ILD.
7. Lung transplant can be considered in all categories.

For rapidly progressive ILD (RP-ILD), as seen, for example in MDA-5:

1. IV methylprednisolone, 1g for 3 days, plus at least 2 others from Rituximab, Cyclophosphamide, IVIg, MMF, JAKi and Tacrolimus
2. For non MDA-5 conditions, it is IV methylprednisolone and at least one, or sometimes two of the others.
3. Again, avoid steroids in SSc-ILD.
4. Rituximab and Cyclophosphamide preferred ahead of MMF and calcineurin inhibitors in RP-ILD.
5. Rituximab preferred ahead of Cyclophosphamide in MDA-5 associated RP-ILD.
6. JAKi useful for slowly progressive MDA-5 but not for RP-ILD.
6. Consider early referral for lung transplant in all eligible cases of RP-ILD.

https://acrjournals.onlinelibrary.wiley.com/doi/epdf/10.1002/art.42861?af=R